Immune Thrombocytopenia (ITP) is a condition where your blood has a lower-than-normal number of platelets. Platelets help your blood clot, so having fewer can cause easy bruising and bleeding. This study tests a medicine called rilzabrutinib on adults and teens with long-lasting ITP. Some people will get this medicine, while others will get a placebo (a pill with no medicine) to see how well rilzabrutinib works. Each person will take 400mg of the study medicine or placebo two times a day.
The study lasts up to 60 weeks. This includes a few weeks to start the study, up to 24 weeks of taking the study medicine, and up to 28 weeks where everyone gets rilzabrutinib. Then, there’s a month of follow-up visits. Some participants may continue longer for extra observations.
- Study length: Up to 60 weeks with extra time possibly needed.
- Age: Teens 12-17 and adults 18+ can join.
- Visits: Regular check-ups are part of the study.